Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II

J. Rybová, J. Ledvinová, J. Sikora, L. Kuchař, R. Dobrovolný,

. 2018 ; 41 (2) : 221-229. [pub] 20171122

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NV15-33297A MZ0 CEP Register

Digital library NLK
Full text - Article
Source

E-resources Online Full text

NLK ProQuest Central from 1999-02-01 to 2018-11-30
Medline Complete (EBSCOhost) from 2009-08-01 to 1 year ago
Health & Medicine (ProQuest) from 1999-02-01 to 2018-11-30

Mucopolysaccharidosis type II (MPSII) is a rare X-linked lysosomal storage disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene (IDS, Xq28). MPSII is characterized by skeletal deformities, hearing loss, airway obstruction, hepatosplenomegaly, cardiac valvular disease, and progressive neurological impairment. At the cellular level, IDS deficiency leads to lysosomal storage of glycosaminoglycans (GAGs), dominated by accumulation of dermatan and heparan sulfates. Human induced pluripotent stem cells (iPSC) represent an alternative system that complements the available MPSII murine model. Herein we report on the reprogramming of peripheral white blood cells from male and female MPSII patients into iPSC using a non-integrating protocol based on the Sendai virus vector system. We differentiated the iPSC lines into IDS deficient and GAG accumulating β-Tubulin III+ neurons, GFAP+ astrocytes, and CNPase+ oligodendrocytes. The lysosomal system in these cells displayed structural abnormalities reminiscent of those previously found in patient tissues and murine IDS deficient neuronal stem cells. Furthermore, quantitative determination of GAGs revealed a moderate increase in GAG levels in IDS deficient neurons and glia. We also tested the effects of recombinant IDS and found that the exogenous enzyme was internalized from the culture media and partially decreased the intracellular GAG levels in iPSC-derived neural cells; however, it failed to completely prevent accumulation of GAGs. In summary, we demonstrate that this human iPSC based model expresses the cellular and biochemical features of MPSII, and thus represents a useful experimental tool for further pathogenesis studies as well as therapy development and testing.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001076
003      
CZ-PrNML
005      
20201112211849.0
007      
ta
008      
190107s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10545-017-0108-5 $2 doi
035    __
$a (PubMed)29168031
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Rybová, Jitka $u Rare Diseases Research Unit, Department of Pediatrics and Adolescent Medicine, Charles University, Ke Karlovu 2, Prague, 12808, Czech Republic.
245    10
$a Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II / $c J. Rybová, J. Ledvinová, J. Sikora, L. Kuchař, R. Dobrovolný,
520    9_
$a Mucopolysaccharidosis type II (MPSII) is a rare X-linked lysosomal storage disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene (IDS, Xq28). MPSII is characterized by skeletal deformities, hearing loss, airway obstruction, hepatosplenomegaly, cardiac valvular disease, and progressive neurological impairment. At the cellular level, IDS deficiency leads to lysosomal storage of glycosaminoglycans (GAGs), dominated by accumulation of dermatan and heparan sulfates. Human induced pluripotent stem cells (iPSC) represent an alternative system that complements the available MPSII murine model. Herein we report on the reprogramming of peripheral white blood cells from male and female MPSII patients into iPSC using a non-integrating protocol based on the Sendai virus vector system. We differentiated the iPSC lines into IDS deficient and GAG accumulating β-Tubulin III+ neurons, GFAP+ astrocytes, and CNPase+ oligodendrocytes. The lysosomal system in these cells displayed structural abnormalities reminiscent of those previously found in patient tissues and murine IDS deficient neuronal stem cells. Furthermore, quantitative determination of GAGs revealed a moderate increase in GAG levels in IDS deficient neurons and glia. We also tested the effects of recombinant IDS and found that the exogenous enzyme was internalized from the culture media and partially decreased the intracellular GAG levels in iPSC-derived neural cells; however, it failed to completely prevent accumulation of GAGs. In summary, we demonstrate that this human iPSC based model expresses the cellular and biochemical features of MPSII, and thus represents a useful experimental tool for further pathogenesis studies as well as therapy development and testing.
650    _2
$a astrocyty $x enzymologie $x patologie $7 D001253
650    _2
$a buněčný rodokmen $7 D019070
650    _2
$a kultivované buňky $7 D002478
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glykosaminoglykany $x metabolismus $7 D006025
650    _2
$a lidé $7 D006801
650    _2
$a iduronátsulfatasa $x genetika $x metabolismus $7 D007066
650    _2
$a indukované pluripotentní kmenové buňky $x enzymologie $x patologie $7 D057026
650    _2
$a lyzozomy $x enzymologie $x patologie $7 D008247
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mukopolysacharidóza II $x enzymologie $x genetika $x patologie $7 D016532
650    _2
$a nervové kmenové buňky $x enzymologie $x patologie $7 D058953
650    12
$a neurogeneze $7 D055495
650    _2
$a neuroglie $x enzymologie $x patologie $7 D009457
650    _2
$a neurony $x enzymologie $x patologie $7 D009474
650    _2
$a prekurzorové buňky oligodendrocytů $x enzymologie $x patologie $7 D000073637
650    _2
$a oligodendroglie $x enzymologie $x patologie $7 D009836
650    _2
$a fenotyp $7 D010641
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ledvinová, Jana $u Rare Diseases Research Unit, Department of Pediatrics and Adolescent Medicine, Charles University, Ke Karlovu 2, Prague, 12808, Czech Republic.
700    1_
$a Sikora, Jakub $u Rare Diseases Research Unit, Department of Pediatrics and Adolescent Medicine, Charles University, Ke Karlovu 2, Prague, 12808, Czech Republic. Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Kuchař, Ladislav $u Rare Diseases Research Unit, Department of Pediatrics and Adolescent Medicine, Charles University, Ke Karlovu 2, Prague, 12808, Czech Republic.
700    1_
$a Dobrovolný, Robert $u Rare Diseases Research Unit, Department of Pediatrics and Adolescent Medicine, Charles University, Ke Karlovu 2, Prague, 12808, Czech Republic. robert.dobrovolny@lf1.cuni.cz.
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 41, č. 2 (2018), s. 221-229
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29168031 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20201112211846 $b ABA008
999    __
$a ok $b bmc $g 1365010 $s 1039199
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 41 $c 2 $d 221-229 $e 20171122 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
GRA    __
$a NV15-33297A $p MZ0
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...